These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 32236684)
41. Bisphosphonates for osteoporosis in people with cystic fibrosis. Conwell LS; Chang AB Cochrane Database Syst Rev; 2012 Apr; (4):CD002010. PubMed ID: 22513903 [TBL] [Abstract][Full Text] [Related]
42. Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration. Safford MM; Barasch A; Curtis JR; Outman R; Saag K J Clin Rheumatol; 2014 Oct; 20(7):357-62. PubMed ID: 25275761 [TBL] [Abstract][Full Text] [Related]
43. The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis. Byun JH; Jang S; Lee S; Park S; Yoon HK; Yoon BH; Ha YC J Bone Metab; 2017 Feb; 24(1):37-49. PubMed ID: 28326300 [TBL] [Abstract][Full Text] [Related]
44. RETRACTED: Efficacy of bisphosphonates against hip fracture in elderly patients with stroke and Parkinson diseases: meta-analysis of randomized controlled trials. Zhang W; Zhu C; Sun M; Ge Y; Yan G J Stroke Cerebrovasc Dis; 2014; 23(10):2714-2724. PubMed ID: 25314942 [TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia. Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349 [TBL] [Abstract][Full Text] [Related]
46. Bisphosphonates for Paget's disease of bone in adults. Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423 [TBL] [Abstract][Full Text] [Related]
47. Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials. Ying ZM; Hu B; Yan SG Orthop Surg; 2020 Aug; 12(4):1293-1303. PubMed ID: 32589343 [TBL] [Abstract][Full Text] [Related]
48. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947 [TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review. Melek J; Sakuraba A Clin Gastroenterol Hepatol; 2014 Jan; 12(1):32-44.e5. PubMed ID: 23981521 [TBL] [Abstract][Full Text] [Related]
51. Bisphosphonate Use and Hospitalization for Hip Fractures in Women: An Observational Population-Based Study in France. Bourrion B; Souty C; Fournier L; Vilcu AM; Blanchon T; Böelle PY; Hanslik T; François M Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444529 [TBL] [Abstract][Full Text] [Related]
53. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. Wang C Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765 [TBL] [Abstract][Full Text] [Related]
54. Association of orthogeriatric care models with evaluation and treatment of osteoporosis: a systematic review and meta-analysis. Van Camp L; Dejaeger M; Tournoy J; Gielen E; Laurent MR Osteoporos Int; 2020 Nov; 31(11):2083-2092. PubMed ID: 32594206 [TBL] [Abstract][Full Text] [Related]
55. Preventing future fractures: effectiveness of an orthogeriatric fracture liaison service compared to an outpatient fracture liaison service and the standard management in patients with hip fracture. Naranjo A; Fernández-Conde S; Ojeda S; Torres-Hernández L; Hernández-Carballo C; Bernardos I; Rodríguez S; Laynez P Arch Osteoporos; 2017 Dec; 12(1):112. PubMed ID: 29230540 [TBL] [Abstract][Full Text] [Related]
57. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis. Ding H; Yang L; Du W; Teng Y; Fu SJ; Tao Y; Lu JZ; Wang ZP Asian Pac J Cancer Prev; 2013; 14(5):3337-43. PubMed ID: 23803126 [TBL] [Abstract][Full Text] [Related]
58. Bisphosphonates and other bone agents for breast cancer. Wong MH; Stockler MR; Pavlakis N Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790 [TBL] [Abstract][Full Text] [Related]
59. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Curtis JR; Westfall AO; Cheng H; Delzell E; Saag KG Osteoporos Int; 2008 Nov; 19(11):1613-20. PubMed ID: 18483689 [TBL] [Abstract][Full Text] [Related]